Foley Hoag Represents Dogma Therapeutics in Sale of Its Oral PCSK9 Inhibitor Program to AstraZeneca
September 17, 2020
Foley Hoag LLP represented Cambridge, MA-based Dogma Therapeutics in the sale of its oral PCSK9 program to global biopharmaceutical company AstraZeneca for upfront as well as downstream payments linked to global regulatory and commercial milestones. The ground-breaking project could prove transformational in the management of hypercholesterolemia and cardiovascular disease. Dogma’s strategic goal in the sale to AstraZeneca is to accelerate access to patients unable to meet target LDL-C.
Dogma has discovered small molecules that directly bind to a novel binding pocket in PCSK9. Guided by dozens of high-resolution x-ray structures of inhibitors bound to the PCSK9 protein, these molecules have allowed rapid optimization to picomolar affinity with exquisite physicochemical attributes and robust LDL-C lowering when dosed orally in preclinical models of hypercholesterolemia.
Foley Hoag attorneys Hemmie Chang, Adrienne Ellman, David Halstead, Nicola Lemay, Kathryn Lumb, Laura Trumbull, Yuliya Kozachenko, Chasse Osborn and Kyrsten Lundh represented Dogma in the transaction.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.